Tus Pharmaceutical Group Co Ltd (000590) - Total Liabilities
Based on the latest financial reports, Tus Pharmaceutical Group Co Ltd (000590) has total liabilities worth CN¥359.74 Million CNY (≈ $52.64 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000590 cash generation efficiency to assess how effectively this company generates cash.
Tus Pharmaceutical Group Co Ltd - Total Liabilities Trend (1995–2024)
This chart illustrates how Tus Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Tus Pharmaceutical Group Co Ltd to evaluate the company's liquid asset resilience ratio.
Tus Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tus Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cryoport Inc
NASDAQ:CYRX
|
USA | $262.35 Million |
|
Refex Industries Limited
NSE:REFEX
|
India | Rs7.71 Billion |
|
Lim Seong Hai Capital Berhad
KLSE:0351
|
Malaysia | RM251.75 Million |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
USA | $29.72 Million |
|
Chemplast Sanmar Limited
NSE:CHEMPLASTS
|
India | Rs45.21 Billion |
|
Cedar Development Co Ltd
SHE:002485
|
China | CN¥623.76 Million |
|
Hamborner REIT AG
XETRA:HABA
|
Germany | €666.28 Million |
|
Jiangsu Holly Corp
SHG:600128
|
China | CN¥3.69 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Tus Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 000590 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tus Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tus Pharmaceutical Group Co Ltd (1995–2024)
The table below shows the annual total liabilities of Tus Pharmaceutical Group Co Ltd from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥412.18 Million ≈ $60.32 Million |
-2.54% |
| 2023-12-31 | CN¥422.92 Million ≈ $61.89 Million |
-8.90% |
| 2022-12-31 | CN¥464.26 Million ≈ $67.94 Million |
+62.61% |
| 2021-12-31 | CN¥285.50 Million ≈ $41.78 Million |
+15.46% |
| 2020-12-31 | CN¥247.27 Million ≈ $36.18 Million |
+10.10% |
| 2019-12-31 | CN¥224.58 Million ≈ $32.86 Million |
-5.19% |
| 2018-12-31 | CN¥236.88 Million ≈ $34.66 Million |
-18.43% |
| 2017-12-31 | CN¥290.40 Million ≈ $42.50 Million |
-20.81% |
| 2016-12-31 | CN¥366.72 Million ≈ $53.66 Million |
-3.91% |
| 2015-12-31 | CN¥381.64 Million ≈ $55.85 Million |
-5.23% |
| 2014-12-31 | CN¥402.71 Million ≈ $58.93 Million |
+42.28% |
| 2013-12-31 | CN¥283.05 Million ≈ $41.42 Million |
+25.56% |
| 2012-12-31 | CN¥225.44 Million ≈ $32.99 Million |
-10.41% |
| 2011-12-31 | CN¥251.62 Million ≈ $36.82 Million |
-13.19% |
| 2010-12-31 | CN¥289.85 Million ≈ $42.41 Million |
+1.66% |
| 2009-12-31 | CN¥285.11 Million ≈ $41.72 Million |
+14.72% |
| 2008-12-31 | CN¥248.53 Million ≈ $36.37 Million |
+2.97% |
| 2007-12-31 | CN¥241.37 Million ≈ $35.32 Million |
-11.94% |
| 2006-12-31 | CN¥274.10 Million ≈ $40.11 Million |
-30.79% |
| 2005-12-31 | CN¥396.04 Million ≈ $57.95 Million |
-3.18% |
| 2004-12-31 | CN¥409.06 Million ≈ $59.86 Million |
-3.98% |
| 2003-12-31 | CN¥426.00 Million ≈ $62.34 Million |
-4.04% |
| 2002-12-31 | CN¥443.96 Million ≈ $64.96 Million |
+6.62% |
| 2001-12-31 | CN¥416.40 Million ≈ $60.93 Million |
+62.51% |
| 2000-12-31 | CN¥256.24 Million ≈ $37.50 Million |
+2.88% |
| 1999-12-31 | CN¥249.06 Million ≈ $36.45 Million |
+83.72% |
| 1998-12-31 | CN¥135.56 Million ≈ $19.84 Million |
+2.52% |
| 1997-12-31 | CN¥132.23 Million ≈ $19.35 Million |
+190.34% |
| 1996-12-31 | CN¥45.54 Million ≈ $6.66 Million |
-39.87% |
| 1995-12-31 | CN¥75.74 Million ≈ $11.08 Million |
-- |
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food in China. It operates through the Production and Sales of Traditional Chinese Medicine; Production and Sales of Western Medicine; and Other Operations segments. The company offers prescription and over-the-counter drugs, such as tonic and heal… Read more